Altimmune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALT research report →
Range $10 – $10
Price Chart
About the company
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist.
- CEO
- Jerome Benedict Durso
- IPO
- 2017
- Employees
- 57
- HQ
- Gaithersburg, MD, US
Get TickerSpark's AI analysis on ALT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $258.80M
- P/E
- -1.93
- PEG
- -0.05
- P/S
- 10403.05
- P/B
- 0.64
- EV/EBITDA
- -2.77
- Div Yield
- 0.00%
- Gross Margin
- -238196.15%
- Op Margin
- -442580.77%
- Net Margin
- -401361.54%
- ROE
- -29.26%
- ROIC
- -23.76%
Latest fiscal year · YoY change
- Revenue
- $41.00K+105.0%
- Gross Profit
- $41.00K+105.0%
- Op Income
- $-94,489,000
- Net Income
- $-88,093,000+7.3%
- EPS
- $-1.00+25.4%
- OCF Growth
- +15.4%
- FCF Growth
- +15.4%
- 52W High
- $6.44
- 52W Low
- $1.32
- 50D MA
- $2.43
- 200D MA
- $3.05
- Beta
- 0.18
- RSI (14)
- 21
- Avg Volume
- 3.94M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Altimmune said pemvidutide is advancing across MASH, AUD, and ALD with Phase 3 MASH enrollment underway, strong confidence in the program, and a cash position that funds operations into the 2029 MASH readout.· November 12, 2026
- PERFORMA Phase 3 in MASH is underway, with more than 70 U.S. sites activated and enrollment starting; management said the 52-week readout is expected in 2029.
- RECLAIM Phase 2 AUD data were described as the strongest in AUD to date, with statistically significant improvements in heavy drinking days, WHO risk drinking level, no heavy drinking days, and supportive PEth data.
- Altimmune emphasized pemvidutide’s differentiated profile: 1-to-1 glucagon/GLP-1 ratio, generally favorable tolerability, no significant drug interactions, and potential benefits across MASH, AUD, and ALD.
- Q3 R&D was $27.0 million versus $15.0 million last year; G&A was $8.7 million versus $5.9 million; net loss was $31.6 million, or $0.15 per share.
- The company ended the quarter with $480 million in cash, cash equivalents, and investments, and said it prefers nondilutive funding for the AUD Phase 3 program.
Q3 2026 revenue was not stated. R&D expense was $27.0 million, up from $15.0 million a year ago, driven mainly by the Phase 3 MASH trial and ongoing ALD work. G&A expense was $8.7 million versus $5.9 million last year. Net loss was $31.6 million, or $0.15 per share, versus a net loss of $19.0 million, or $0.21 per share, in Q3 2025. The company ended the quarter with $480 million in cash, cash equivalents, and investments. Management said year-to-date cash burn is in line with plan and should fund operations through the PERFORMA 52-week readout expected in 2029. For AUD, management said it expects greater clarity after the FDA end-of-Phase 2 meeting in December and prefers nondilutive funding such as royalty debt or a strategic partnership.
Jerry Durso struck an upbeat, execution-focused tone, saying Altimmune enters the final months of the year with strong confidence in pemvidutide and a strategy it is ‘laser-focused’ on executing. He framed pemvidutide as a potential broad liver franchise spanning MASH, AUD, and ALD, and pointed to ASLD/Liver Meeting data as strengthening the company’s conviction. He also highlighted progress on PERFORMA site activation, the FDA meeting for AUD next month, and recent board additions as part of the company’s move into a later-stage biotech profile.
Gregory Weaver focused on the cost base, balance sheet, and runway. He said Q3 R&D was $27.0 million, including $20.3 million of direct pemvidutide development costs, and G&A was $8.7 million, with higher compensation and professional fees contributing to the increase. He reported $480 million in cash, cash equivalents, and investments, said cash burn is tracking to plan, and stated that this runway should extend through the PERFORMA 52-week readout expected in 2029. He also said Altimmune wants nondilutive funding for the AUD Phase 3 program, including royalty debt or a strategic partnership.
Analysts focused on PERFORMA enrollment pace, trial design assumptions, and how the AUD program will be funded and advanced. Management said PERFORMA is tracking as planned, with over 70 U.S. sites activated and ex-U.S. sites to follow, but declined to give specific patient counts or full statistical assumptions. On AUD, management said the December FDA meeting is the key next step, with minutes typically following within 30 days, and it expects to refine the Phase 3 design and funding approach after that. They also said they are leaning toward a WHO risk drinking level primary endpoint, while keeping no heavy drinking days as a key secondary endpoint.
The company believes it now has multiple data points supporting pemvidutide’s mechanism and profile, including favorable MASH biomarker/fibrosis signals and robust AUD efficacy. Management repeatedly stressed that the drug may have a differentiated role because it can address both drinking behavior and liver injury, which they see as a key advantage in moderate-to-severe AUD and liver-impaired patients. The cash position also gives Altimmune time to advance PERFORMA while it works through the AUD regulatory path.
The biggest risks are execution and time: PERFORMA’s 52-week readout is not expected until 2029, and AUD Phase 3 timing remains unresolved pending FDA feedback and funding decisions. Management also acknowledged it is still early in PERFORMA, with ex-U.S. activation still to come and no patient-count disclosure yet, so enrollment and trial pace remain open questions. On the commercial side, management noted that only a small share of AUD patients currently receive pharmacotherapy, suggesting adoption and reimbursement may be challenging even if approval is achieved.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.4%
- Shares Outstanding
- 194.59M
- Float Shares
- 183.71M
of shares held by institutions
222 13F filers
Buy/sell ratio 1.83. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 20.96M | ▲ 574.98K |
| Deep Track Capital, LP | 19.25M | ▲ 19.25M |
| Tcg Crossover Management, LLC | 10.00M | ▲ 10.00M |
| Vanguard Group Inc | 9.49M | ▲ 3.12M |
| State Street Corp | 8.36M | ▼ 3.74M |
| Vanguard Portfolio Management LLC | 8.11M | ▲ 777.29K |
| Vanguard Capital Management LLC | 7.81M | ▼ 364.83K |
| Viking Global Investors LP | 6.70M | ▲ 6.70M |
| Ra Capital Management, L.P. | 6.50M | ▲ 6.50M |
| Marshall Wace, Llp | 5.43M | ▼ 1.41M |
| Geode Capital Management, LLC | 4.88M | ▼ 126.82K |
| Woodline Partners LP | 3.40M | ▲ 3.40M |
Held by 169 ETFs
Biggest fund positions in ALT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | MENZIUSO RICHARD THOMAS | buy | 10,000 |
| Nov 13, 26 | WEAVER GREGORY L | buy | 10,000 |
| Nov 13, 26 | Pisano Wayne | buy | 10,000 |
| Nov 13, 26 | Durso Jerome Benedict | buy | 30,700 |
| Nov 11, 26 | WEAVER GREGORY L | other | 18,750 |
| Nov 11, 26 | WEAVER GREGORY L | other | 5,672 |
| Nov 11, 26 | WEAVER GREGORY L | other | 18,750 |
| Nov 2, 26 | Greenleaf Peter | other | 160,000 |
| Nov 2, 26 | Greenleaf Peter | other | 0 |
| Nov 2, 26 | Howarth Alex G. | other | 160,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALT coverage
Recent articles, reports, and earnings notes.

Should You Buy Corxel US Before the SPAC Merger Closes?
Corxel US is a clinical-stage biopharmaceutical company developing oral obesity and cardiometabolic therapies, and it is going public through a merger with Amanat Acquisition Corp. (Nasdaq: AMAN). The deal is expected to close in the first half of 2027, but shareholders should watch the cash raise and redemption math closely because dilution and trust leakage could reshape the setup.

Should You Buy the Palatin Technologies IPO? Here's the Setup
Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.
Want a deeper read on ALT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
globenewswire.com · Nov 19
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
zacks.com · Nov 13
Altimmune: Still Too Late And Too Capital-Intensive
seekingalpha.com · Nov 12
Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
What Altimmune (ALT) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
globenewswire.com · Nov 12
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
globenewswire.com · Nov 12
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.